OncoMatch/Clinical Trials/NCT07200102
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Is NCT07200102 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies Selinexor for multiple myeloma.
Treatment: Selinexor — The outcomes in patients with relapsed or refractory multiple myeloma refractory to triple-therapy remain poor. These patients are eligible for chimeric antigen receptor T-cells (CAR-T), which rely on redirecting autologous T-cells to clear myeloma cells by targeting B-cell maturation antigen (BCMA). BCMA CAR-T therapy is not curative, and unlike autologous stem cell transplant, there is currently no standard for maintenance therapy post CAR-T which could potentially increase MRD rates and extend progression-free survival. Selinexor is an exportin (XPO1) inhibitor with direct anti-tumor effect used often as an adjunct with other agents as bridging therapy prior to CAR-T. As selinexor does not affect T-cell yields or fitness, T-cell collection on selinexor for CAR-T manufacturing is safe. The aim of this study is to evaluate the safety and toxicity of selinexor in relapsed or refractory multiple myeloma patients with high-risk features (adverse risk cytogenetics, less than complete response (CR) post CAR-T, or extramedullary disease) following BCMA CAR-T therapy. The investigators hypothesize that selinexor as maintenance therapy following CAR-T has the potential to act synergistically with CAR-T cells leading to more durable responses.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Multiple Myeloma
Biomarker criteria
Required: TP53 deletion
Deletion of 17p with a cancer clonal fraction (CCF) ≥20%, assessed on CD138-positive/purified plasma cells
Required: TP53 mutation
TP53 mutation identified using a validated next-generation sequencing (NGS)-based assay
Required: WHSC1 t(4;14)
Presence of t(4;14)...in combination with either gain/amplification of 1q (1q+) and/or deletion of 1p32
Required: IGH t(14;16)
Presence of t(14;16)...in combination with either gain/amplification of 1q (1q+) and/or deletion of 1p32
Required: IGH t(14;20)
Presence of t(14;20)...in combination with either gain/amplification of 1q (1q+) and/or deletion of 1p32
Required: CHR1Q gain/amplification
gain/amplification of 1q (1q+)
Required: CHR1P32 deletion
deletion of 1p32
Required: CHR1P32 monoallelic deletion
Monoallelic deletion of 1p32 occurring with gain/amplification of 1q
Required: CHR1P32 biallelic deletion
Biallelic deletion of 1p32
Required: B2M elevated expression (≥5.5 mg/L)
Serum β2-microglobulin ≥5.5 mg/L in the setting of normal renal function, defined as serum creatinine <1.2 mg/dL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
received at least 1 prior line of therapy, including a proteasome inhibitor
Must have received: immunomodulatory agent
received at least 1 prior line of therapy, including...an immunomodulatory agent
Cannot have received: selinexor or XPO1 inhibitor
Has received selinexor or another XPO1 inhibitor post-CART
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.0 K/cumm; platelets ≥ 50 K/cumm; hemoglobin ≥ 8.5 g/dL without blood transfusion within 7 days before C1D1
Kidney function
Calculated creatinine clearance ≥ 15 mL/min by Cockcroft-Gault; serum creatinine <1.2 mg/dL for high-risk β2-microglobulin criterion
Liver function
Total bilirubin ≤ 1.5 x IULN; patients with Gilbert's syndrome must have a total bilirubin < 3 x IULN. AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN
Cardiac function
congestive heart failure of NYHA class ≥ 3 or known left ventricular ejection fraction of < 40%, or myocardial infarction within 3 months prior to C1D1 of selinexor therapy [excluded]
Adequate bone marrow and organ function as defined below: Absolute neutrophil count ≥ 1.0 K/cumm; Platelets ≥ 50 K/cumm; Hemoglobin ≥ 8.5 g/dL without blood transfusion within 7 days before C1D1. Total bilirubin ≤ 1.5 x IULN; patients with Gilbert's syndrome must have a total bilirubin < 3 x IULN. AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN. Calculated creatinine clearance ≥ 15 mL/min by Cockcroft-Gault
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07200102 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior selinexor or XPO1 inhibitor disqualifies patients from enrollment.
Does this trial require TP53?
Yes, TP53 deletion is a required biomarker for enrollment.
Does this trial require TP53?
Yes, TP53 mutation is a required biomarker for enrollment.
Does this trial require WHSC1?
Yes, WHSC1 t(4;14) is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages